MariTide vs Zepbound: Monthly Versus Weekly Injections

The headline difference between MariTide and Zepbound is dosing frequency: MariTide is designed for once-monthly injection, while Zepbound is weekly, and their trial weight-loss figures are surprisingly close. MariTide is investigational; Zepbound is approved and available. Both are strong performers, so the comparison largely comes down to whether monthly dosing (once available) would outweigh Zepbound’s proven, ready-now status. Here’s how they stack up.

The Dosing Difference

The most striking contrast is how often you’d take each. Zepbound (tirzepatide) is a weekly injection, which is standard for this drug class and manageable for most people. MariTide is engineered for once-monthly dosing (or potentially even less frequent), thanks to a long-acting design. For a chronic condition requiring ongoing treatment, fewer injections could meaningfully improve adherence and convenience, which is MariTide’s central pitch.

Head to Head

An Interesting Mechanistic Twist

Here’s a subtlety worth noting. Both drugs involve the GIP receptor, but in opposite ways. Zepbound activates GIP (alongside GLP-1), while MariTide blocks GIP (alongside activating GLP-1). It seems counterintuitive that activating and blocking the same receptor could both aid weight loss, yet both approaches work in trials, which reflects how much remains to be understood about GIP’s role. The practical upshot is that these are genuinely different drugs despite similar weight-loss numbers.

Weight Loss: Essentially a Tie

On weight loss, they’re remarkably close. MariTide’s phase 2 data, published in the New England Journal of Medicine in 2025, showed up to about 20% weight loss at 52 weeks, and notably the weight loss hadn’t plateaued, suggesting more might be possible. Zepbound produced up to about 21% in its pivotal trial. So on results alone, they’re roughly comparable, with MariTide potentially climbing higher over longer treatment.

Availability: Zepbound Wins Decisively

This is the deciding factor for now. Zepbound is approved and available, with an established track record. MariTide, despite its appealing monthly dosing, is investigational and only accessible through clinical trials, with phase 3 testing underway. Consider a hypothetical patient drawn to the idea of monthly injections: it’s an attractive concept, but it’s not something they can choose today, whereas Zepbound is ready now. A monthly option that isn’t available can’t beat a weekly one that is.

What This Means for You Right Now

MariTide is not available, and TrimRx does not offer it. Zepbound (tirzepatide) is among the brand options TrimRx offers, alongside compounded tirzepatide and compounded semaglutide and other brand GLP-1 medications. If you want strong, proven weight loss now, tirzepatide-based treatment delivers comparable results to what MariTide showed in trials, and you can actually start it. MariTide remains a promising future option to watch.

Frequently Asked Questions

Is MariTide as effective as Zepbound?

In trials, they’re close: MariTide showed up to about 20% weight loss and Zepbound up to about 21%. MariTide’s weight loss hadn’t plateaued at one year, so it might climb higher with longer use, but on current data they’re roughly comparable.

Is a monthly injection better than weekly?

Monthly dosing means fewer injections, which could improve convenience and adherence for a long-term treatment. Whether that makes MariTide “better” depends on the person, and it’s moot for now since MariTide isn’t available while Zepbound is.

Can I get MariTide?

No. MariTide is investigational and available only through clinical trials. Zepbound is FDA approved and available, and TrimRx offers tirzepatide-based options.

To focus on what you can actually start with today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. MariTide is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.